Although the existence of blood platelets had been known for many years it was not until 1882 that Bizzozero (1) called attention to the role of platelets in blood coagulation. Morawitz (2), twenty years later, was among the first to consider the specific chemical contribution of the platelet to the clotting process.
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Howell (3) , in 1912, demonstrated the presence of an unsaturated phosphatide ("kephalin") in thromboplastic substances of tissue origin. Mills (4) , in 1927, showed cephalin to be present in blood platelets, and the following year Haurowitz and Sladek (5) published results of chemical analysis of horse platelets, reporting a lipid content of 12 per cent of dry weight. The first convincing data relating the cephalin content of platelets to acceleration of coagulation were supplied by Chargaff, Bancroft and Stanley-Brown (6) . These workers also reported at that time what has recently been emphasized again (7, 8) : phosphatides from other natural sources (soy bean, yeast) also were capable of accelerating blood clotting in vitro. Erickson, Williams, Avrin and Lee (9) , confirmed the results of Chargaff and associates relating to platelet phospholipid content. Wallach, Surgenor and Steele (10) , identified phosphatidyl ethanolamine and phosphatidyl serine in human platelets. Subsequently the presence of inositol phosphatide was noted ( 11, 12) .
Wooldridge, in 1886 (13) , demonstrated a coagulant effect of substances obtained from red cells by both aqueous and lipid solvents. With small doses of these extracts administered intravenously to dogs, Wooldridge also observed a hypocoagulable state similar to that noted in animals infused with thromboplastin (14) (15) (16) . Much more recently a number of investigators (11, (17) (18) (19) (20) (21) , have again demonstrated active coagulant substances in red cell hemolysates or extracts. Further studies have demonstrated that the coagulant activity resides in a lipoprotein (22, 23) or a lipid (11) . The exact chemical nature of these thromboplastic substances derived from platelets and red blood cells has been the subject of much investigation since Wooldridge's publication (13) . That the primary coagulant activity resides in the cephalin fraction was shown by the work of a number of investigators (3, (24) (25) (26) (27) in the period between 1886 and 1930. In 1921, Zunz and LaBarre (28) demonstrated that an excess of cephalin inhibited coagulation and that lecithin, inactive alone (27) , potentiated the effects of cephalin in combination. Folch (29) (42, 43) have attributed an antithromboplastic activity to phosphatidyl serine but, more recently, Barkhan, Silver, daCosta and Tocantins (44) have reported that phosphatidyl serine can act as an accelerator or as an inhibitor of coagulation depending upon the experimental conditions. This possibility had been predicted by Wolf (45) , based on observationls by Overman (46) .
It is thus apparent that the role of platelet phospholipids in coagulation has not been precisely de- A. Isolation of platelets from whole blood. Blood was obtained from normal adult volunteers; it was collected by gravity flow into plastic bags containing 1.5 per cent disodium dihydrogen ethylenediaminetetraacetate in 0.7 per cent NaCl,1 employing a plastic donor set.2 A proportion of 9 volumes of blood to 1 volume of anticoagulant was used. Forty ml aliquots were then gently decanted into silicone-coated3 glass tubes and these were centrifuged at room temperature at 300 G for 15 minutes. All glassware used in collection and transfer of platelet-containing plasma was similarly treated. All glassware used in the coagulation studies was acidcleaned. The supernatant platelet-rich plasma was transferred by pipette to glass centrifuge tubes. Aliquots of platelet-rich plasma were then taken for platelet and white cell counting, and aliquots to be used in coagulation studies were stored at 4°C in glass tubes. The platelet-rich plasma thus obtained had fewer than 300 leukocytes per cu mm, and was completely free of red cells. The platelet-rich plasma was then centrifuged at 2,000 G at 40 C. The supernatant platelet-poor plasma thus obtained was decanted into other centrifuge tubes and again centrifuged at 40 C for 30 minutes at 2,000 G. This supernatant plasma had fewer than 1,000 platelets per cu mm (49) and was considered to be "plateletpoor." The sedimented platelets obtained after the first 2,000 G centrifugation were pooled and washed 3 times with isotonic NaCl solution and resedimented by centrifugation at 40 C for 5 minutes at 900 G. The platelets thus obtained were then subjected to lipid extraction and analysis.
B. Extractiont, separation, and measurement of platelet and red cell lipids. The methods used for the extraction, separation, and quantification of the red cell lipids were those previously employed (48) . The chromatographic methods of lipid separation have been described in detail by Marinetti, Erbland and Kochen (47) . The washed platelets were extracted 3 times with 30 ml of chloroformmethanol (1: 1)4; the platelet residue was separated by centrifugation and the supernatants were pooled and evaporated to complete dryness under partial vacuum with a nitrogen atmosphere. The residue of the pooled supernatant was re-extracted with 30 ml of chloroform; this extract was filtered through fritted glass, evaporated to dryness and constant weight under partial vacuum and a nitrogen atmosphere, and the lipids weighed. The entire extraction procedure was carried out at 370 C. The lipids were then dissolved in sufficieint beinzenie to achieve a concentration of 5 to 10 mg per ml. Total lipid phosphorus, usinig the method of Berenblum and Chain (50) was determined oIn aliquots of this solution. The total cholesterol content was determined by the method of Bloor (51) . The (48) . The similarity in composition of the lipids of the red cells and of the platelets is apparent. The proportion of phospholipid in each case is just less than 70 per cent of the total lipids. The red cell lipids contain significantly more phosphatidyl serine, and less lecithin, than do the platelet lipids. The lipids grouped into "others" include a small amount of lyso-lecithin, glycolipids, traces of free fatty acids, neutral fats, and cholesterol esters.
The lipids of human plasma have been studied employing similar techniques, and will be reported elsewhere (55) . We have been unable to identify any phosphatidyl serine in fasting normal human plasma that had been gathered with care to avoid red cell and platelet lysis while being rendered cell-and platelet-free. Efforts to demonstrate phosphatidyl serine in such plasma have included in vivo P32-labeling of the plasma lipids, and concentration of lipids from large volumes of plasma. Approximately 1 mg of lipid was consistently obtained from the platelets present in 10 ml samples of normal whole blood. This is approximately seven times the quantity found by Marcus and Spaet (39) . This difference can best be attributed to differences in techniques of collecting and processing the platelets. By performing platelet counts (49) on the whole blood and on the platelet-rich plasma obtained from that whole blood, it was evident that approximately 80 per cent of the platelets initially present in the whole blood were obtained for the lipid extraction and analysis. Thus, approximately 1.25 mg of platelet lipid is actually present in 10 ml of whole blood. By comparison, the red cells of 10 ml of normal whole blood contain approximately 26 mg of lipid.
B. In vitro effect of liPids on coagulation. Figure 3 summarizes the results of a typical series of in vitro coagulation experiments. The serum derived from the clotting of platelet-poor plasma without added lipid contained 90 per cent of the prothrombin initially present in the plasma. Plasma to which 5 ug of complete platelet or red cell lipid had been added yielded serum containing less than 15 per cent of the plasma prothrombin. The clotting of platelet-rich plasma also yielded serum containing about 15 per cent of the prothrombin initially present in the plasma. Adding 5 ug of phosphatidyl serine to platelet-poor plasma resulted in serum containing only small amounts of prothrombin. The platelets present in 1 double bonds with hydrogen, 2) hydroxylation and epoxylation of the fatty acid double bonds, and 3) acylation of the free amino groups. Each'of these changes rendered the lipids inactive in these test systems, while the unmodified lipids produced great activity when equivalent amounts were tested.
Several synthetic phospholipids were also tested.5 These were: 1) phosphatidyl seryl glycyl glycine, an analog of phosphatidyl serine, in which two molecules of glycine are present in a peptide linkage at the usual position of the single serine molecule; 2) dioleyl phosphatidyl ethanolamine, in which both fatty acid groups are oleic acid; and 3) 5 Provided by Dr. E. Baer, Department of Biochemistrv University of Toronto, Canada. 
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DISCUSSION
The observations reported here confirm the presence of a variety of phosphatides including phosphatidyl ethanolamine, phosphatidyl serine, lecithin, sphingomyelin, and inositol phosphatide in human platelets. Cholesterol constitutes a significant portion of the platelet lipids, but only a very small amount is present as cholesterol ester, free fatty acids, neutral fat, or lysolecithin.
Of particular interest is the presence in platelets of phosphatidyl serine, which appears to be uniquely a cellular phospholipid. It has not been possible to identify phosphatidyl serine by any method in normal human plasma gathered with care to avoid platelet or red cell lysis. Studies utilizing isotopic labeled lipids (55) have also been unable to detect phosphatidyl serine in cell-free plasma. Phosphatidyl ethanolamine, however, and each of the other cellular lipids, can be identified in normal cell-free human plasma. Axelrod, Reichenthal and Brodie (56) have reported small amounts of phosphatidyl serine in two samples of human plasma, but they did not indicate whether the plasma samples were first rendered cell-and platelet-free.
At least 100 pg of platelet lipid is present in 1 ml of normal human whole blood. Five ,ug of platelet lipid furnishes, in vitro, sufficient coagulant activity to generate maximally the thromboplastin in 2.0 ml of reaction mixture (52) or to activate the prothrombin in 1 ml of platelet-poor plasma. It thus seems likely that there is normally an excess of both plasma and platelet coagulant factors.
Although there has been general agreement that the platelet contribution to coagulation is at least partly phospholipid-in nature (30-33, 35, 36, 39-42, 44, 45) , there has been no unanimity of opinion as to whether this is a single lipid compound (35) . The data presented here suggest that one phospholipid, phosphatidyl serine, is the most potent phospholipid in the coagulation process. The activity it possesses is potentiated by, but is not dependent upon, lecithin. Thus, the same activity attributed to 5 JLg of complete platelet lipid in the prothrombin consumption or thromboplastin generation tests can be achieved by the use of a combination of phosphatidyl serine and lecithin only, equal to the amounts in the 5 ug of the complete lipid. None of the other lipids, singly or in combination as they are represented in the complete lipid extract, demonstrated equivalent activity. The potentiation by lecithin of the coagulant effect of phosphatidyl serine has been reported by others (34, (37) (38) (39) . The data presented here, however, differ from those reported by Therriault, Nichols and Jensen (37, 38) . They demonstrated a coagulant effect of phosphatidyl serine and lecithin, but demonstrated no coagulant effect for phosphatidyl serine alone.
Phosphatidyl ethanolamine and sphingomyelin, and to a lesser degree, phosphatidyl ethanolamine and lecithin, potentiate the clotting mechanism as measured in our test systems but require concentrations that greatly exceed those found in normal human platelets.
The similarity in lipid content of human platelets and red blood cells was shown in Table I (34, 37, 38) . We have not found it necessary to employ a nonpolar solvent to produce effective combinations of lecithin and phosphatidyl serine. The potentiating effect of lecithin occurs if the phosphatides are combined and emulsified in normal saline or in plasma. The phospholipids used by some of these workers (34, 37, 38) were obtained from animal brains. The phospholipids used in our experiments were obtained from human platelets and red cells, and it is possible that species differences account for some of the differences in findings. The observations reported here are difficult to reconcile with those reported earlier (30) (31) (32) (33) (40) (41) (42) (43) 2. Within the limits of resolution of the chromatographic system, it is clear that only one phospholipid, phosphatidyl serine, which is present in both platelet and red cells, but not in plasma, was able to substitute for the whole platelet lipid extract in the two in vitro coagulation systems used in these studies.
3. The coagulant activity of phosphatidyl serine was enhanced by the presence of lecithin.
4. Phosphatidyl ethanolamine, inactive alone in the test system employed, displayed some coagulant activity when combined with lecithin, and a lesser activity when combined with sphingomyelin.
5. The coagulant activity of the complete platelet lipid extract could be reproduced by employing only the amounts of phosphatidyl serine and lecithin contained in the whole lipid extract.
